1. Home
  2. STTK vs GSIT Comparison

STTK vs GSIT Comparison

Compare STTK & GSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • GSIT
  • Stock Information
  • Founded
  • STTK 2016
  • GSIT 1995
  • Country
  • STTK United States
  • GSIT United States
  • Employees
  • STTK N/A
  • GSIT N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • GSIT Semiconductors
  • Sector
  • STTK Health Care
  • GSIT Technology
  • Exchange
  • STTK Nasdaq
  • GSIT Nasdaq
  • Market Cap
  • STTK 112.6M
  • GSIT 115.2M
  • IPO Year
  • STTK 2020
  • GSIT N/A
  • Fundamental
  • Price
  • STTK $1.98
  • GSIT $12.83
  • Analyst Decision
  • STTK Hold
  • GSIT
  • Analyst Count
  • STTK 5
  • GSIT 0
  • Target Price
  • STTK $3.00
  • GSIT N/A
  • AVG Volume (30 Days)
  • STTK 411.4K
  • GSIT 293.8K
  • Earning Date
  • STTK 11-13-2025
  • GSIT 10-30-2025
  • Dividend Yield
  • STTK N/A
  • GSIT N/A
  • EPS Growth
  • STTK N/A
  • GSIT N/A
  • EPS
  • STTK N/A
  • GSIT N/A
  • Revenue
  • STTK $2,997,000.00
  • GSIT $22,130,000.00
  • Revenue This Year
  • STTK N/A
  • GSIT N/A
  • Revenue Next Year
  • STTK N/A
  • GSIT N/A
  • P/E Ratio
  • STTK N/A
  • GSIT N/A
  • Revenue Growth
  • STTK N/A
  • GSIT 6.14
  • 52 Week Low
  • STTK $0.69
  • GSIT $1.62
  • 52 Week High
  • STTK $2.71
  • GSIT $5.89
  • Technical
  • Relative Strength Index (RSI)
  • STTK 48.57
  • GSIT 90.92
  • Support Level
  • STTK $1.72
  • GSIT $4.80
  • Resistance Level
  • STTK $2.71
  • GSIT $5.50
  • Average True Range (ATR)
  • STTK 0.22
  • GSIT 1.20
  • MACD
  • STTK -0.09
  • GSIT 0.61
  • Stochastic Oscillator
  • STTK 25.05
  • GSIT 72.31

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.

Share on Social Networks: